revolutionizing proteomics to transform healthcare somalogic was founded in 2000 with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected and diagnosed. building on the previous decade of aptamer research, somalogic scientists have developed a new proteomics technology that overcomes the significant challenges of current technologies, and which has multiple applications across the biological and medical sciences. our mission is to leverage our proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare. if you would like to learn more about somalogic, contact us at information@somalogic.com or 303-625-9000
Company profile
Ticker
SLGCW, SLGCW
Exchange
Website
CEO
Adam Taich
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Medpace • Incyte • Zymergen • OmniAb • National Research ...
Former names
CM Life Sciences II Inc.
SEC CIK
Corporate docs
Subsidiaries
SomaLogic Operating Co., Inc. • SomaLogic Limited • SomaLogic Singapore PTE. LTD. ...
IRS number
854298912
SLGCW stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
16 Jan 24
EFFECT
Notice of effectiveness
12 Jan 24
EFFECT
Notice of effectiveness
12 Jan 24
POS AM
Prospectus update (post-effective amendment)
5 Jan 24
POS AM
Prospectus update (post-effective amendment)
5 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
5 Jan 24
25-NSE
Exchange delisting
5 Jan 24
Transcripts
SLGCW
Earnings call transcript
2023 Q3
8 Nov 23
SLGCW
Earnings call transcript
2023 Q2
14 Aug 23
SLGCW
Earnings call transcript
2023 Q1
11 May 23
SLGCW
Earnings call transcript
2022 Q4
27 Mar 23
SLGCW
Earnings call transcript
2022 Q3
14 Nov 22
SLGCW
Earnings call transcript
2022 Q2
16 Aug 22
SLGCW
Earnings call transcript
2022 Q1
13 May 22
SLGCW
Earnings call transcript
2021 Q4
30 Mar 22
SLGCW
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 306.75 mm | 306.75 mm | 306.75 mm | 306.75 mm | 306.75 mm | 306.75 mm |
Cash burn (monthly) | 16.32 mm | 6.59 mm | 9.36 mm | 12.82 mm | 7.12 mm | 9.77 mm |
Cash used (since last report) | 196.45 mm | 79.27 mm | 112.66 mm | 154.30 mm | 85.71 mm | 117.60 mm |
Cash remaining | 110.30 mm | 227.48 mm | 194.09 mm | 152.45 mm | 221.04 mm | 189.15 mm |
Runway (months of cash) | 6.8 | 34.5 | 20.7 | 11.9 | 31.0 | 19.4 |
Institutional ownership, Q2 2024
0.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 110.21 mm |
Total shares | 10.37 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Novartis Pharma | 10.37 mm | $110.21 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jan 24 | Robert Barchi | Common Stock | Sale back to company | Dispose D | No | No | 0 | 7,630 | 0.00 | 0 |
5 Jan 24 | Robert Barchi | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,430 | 0.00 | 0 |
5 Jan 24 | Robert Barchi | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.3 | 20,600 | 47.38 k | 0 |
5 Jan 24 | Robert Barchi | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.08 | 20,600 | 187.05 k | 0 |
5 Jan 24 | Robert Barchi | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 11.85 | 46,705 | 553.45 k | 0 |
5 Jan 24 | Carey Thomas D. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.74 | 185,400 | 508.00 k | 0 |
5 Jan 24 | Anne H. Margulies | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 2,472,270 | 0.00 | 0 |
5 Jan 24 | Anne H. Margulies | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 10,132,005 | 0.00 | 0 |
5 Jan 24 | Anne H. Margulies | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 6,800,000 | 0.00 | 0 |
5 Jan 24 | Anne H. Margulies | Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,430 | 0.00 | 0 |